Endovascular Engineering, Inc. has named Dan Rose as Chief Executive Officer (CEO) while former CEO and founding team member Mike Rosenthal will continue as Chief Operating Officer. Dan Rose, with his extensive experience in the medical technology industry, will lead the company through the next phase of transformative growth.
Company Information
Company
Endovascular Engineering
Location
3925 Bohannon Dr
Menlo Park, California, United States
About
Endovascular Engineering, Inc. ("E2") is at the forefront of transforming venous thromboembolism (VTE) treatment with the Hēlo™ Thrombectomy System, a novel technology designed for the treatment of pulmonary embolism. As a venture-backed medical technology innovator with multiple strategic investors, E2 is dedicated to developing and deploying groundbreaking solutions that advance the standard of care in clot removal. The company's technology platform represents the convergence of clinical insight and engineering excellence, aimed at addressing the complex challenges in VTE intervention.
Menlo ParkBiotechnologyHealth CareMedical Devicemedical devices